This biotechnology company uses artificial intelligence to identify and analyze circular RNA for therapeutic development. Their platform focuses on non-coding RNA mechanisms to target previously undruggable diseases, enabling biopharmaceutical companies to develop novel treatments.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SLFounders
Product
Problem
Many diseases are considered "undruggable" due to the limitations of traditional drug discovery methods in targeting complex biological mechanisms. Current approaches often fail to address non-coding RNA's role in these diseases, leaving a significant gap in therapeutic development. There is a need for innovative methods to identify and analyze RNA structures for effective drug design.
Solution
CircNova is a biotechnology company that leverages its AI NovaEngine™ to discover and analyze circular RNA (circRNA) for therapeutic development. The company's platform focuses on non-coding RNA mechanisms of action to target previously undruggable disease targets, addressing major unmet clinical needs. By using AI-guided RNA-folding and active structure prediction coupled with high-throughput RNA synthesis, CircNova enhances the efficiency of developing effective therapeutic candidates. The AI NovaEngine™ predicts circRNA structures using deep learning, enabling therapeutic design for diseases like Triple-negative Breast Cancer.
Target Audience
CircNova's primary customers are biopharmaceutical companies seeking novel therapeutic targets and innovative drug discovery platforms, as well as research institutions focused on RNA-based therapeutics.
Features
- AI NovaEngine™ for circRNA generation, analysis, and identification
- Deep-learning algorithms for predicting circular RNA structures
- AI-guided RNA-folding and active structure prediction
- High-throughput RNA synthesis for efficient therapeutic candidate development
- Focus on non-coding RNA with diverse mechanisms of action
- Development of therapeutics for previously "undruggable" disease targets